Self-Assembling Peptides Form Protective Nanonetworks That Kill Bacteria and Resist Breakdown

Researchers designed a new class of antimicrobial peptides inspired by gemini surfactants — twin-headed soap-like molecules. The lead peptide IPr self-assembles into nanoribbon networks through non-covalent forces, which dramatically improves its resistance to enzyme degradation. IPr killed all 10 tested bacterial strains (both Gram-negative and Gram-positive), resisted protease breakdown, and tolerated physiological salt concentrations. It works by disrupting bacterial membranes, triggering a cascade of reactive oxygen species accumulation and ATP leakage. In a mouse peritonitis model, IPr showed excellent biocompatibility and significantly reduced systemic bacterial infection severity.

The team designed gemini surfactant-like peptide templates and synthesized variants. They tested antibacterial activity against 10 bacterial strains, protease stability, and salt tolerance. Molecular dynamics simulations and structural characterization (nanoribbon/nanonetwork visualization) elucidated the self-assembly mechanism. Mechanism studies measured membrane disruption, ROS accumulation, and ATP leakage. In vivo efficacy was tested in a mouse peritonitis infection model with biocompatibility assessment.

The stability problem is the Achilles' heel of antimicrobial peptides — enzymes in the body break them down before they can work. This study offers a fundamentally different solution: instead of chemically modifying individual peptides, they designed peptides that spontaneously self-assemble into protective nanostructures. The nanonetwork formation shields the peptides from enzymatic attack without requiring unnatural amino acids or cyclization, providing a new design template for stable peptide antibiotics.

The antimicrobial peptide field has been searching for ways to overcome the stability barrier for decades. Most approaches involve chemical modifications like cyclization or D-amino acid substitution. This self-assembly strategy is fundamentally different — the peptides protect themselves by forming supramolecular structures. If this design template proves generalizable, it could create a whole new category of stable peptide antibiotics built from simple, natural building blocks.

Preclinical study with no human data. Only one infection model (peritonitis) was tested in vivo. Specific MIC values and quantitative infection reduction data were not provided in the abstract. The long-term stability of the self-assembled nanonetworks under varying physiological conditions is not discussed. Manufacturing scalability and cost are not addressed.